Safety and Efficacy of Oral NXC-736 in Adult Participants With Severe Alopecia Areata

Status:
Not yet recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Phase 2

NEXTGEN Bioscience